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Fig. 1. Overnight cultures (top) and pour plates 
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Abstract: 
Studies in Pseudomonas aeruginosa have suggested that the TonB energy transduction 
system directly contributes to efflux-mediated antibiotic resistance, ostensibly by energizing 
one or more efflux systems.  We have found ∆tonB strains of Escherichia coli to similarly be 
more sensitive to certain antibiotics relative to wild-type strains.  To test the hypothesis that 
this enhanced sensitivity involved the energization of efflux systems, sensitivity patterns for a 
variety of antibiotics were evaluated using a set of strains differentially lacking genes encoding 
the Acr efflux system, the universal outer membrane efflux portal TolC, and TonB.  No 
correlation was evident between the resistance phenotypes of TonB system mutants and efflux 
mutants.  Addition comparisons using Tol system components excluded the possibility that the 
increased sensitivity of TonB strains involved disruption of the barrier function of the outer 
membrane.  Further comparisons, using strains in which iron transport was altered and cells 
were grown under iron limiting conditions, suggest that enhanced sensitivity to select 
antibiotics is simply another aspect of the pleomorphic tonB phenotype attributable to iron 
starvation. Understanding the TonB system is important for public health. 
 
Introduction: 
Gram-negative bacteria have an inner (cytoplasmic) and outer membrane with a 
periplasmic space between. The outer membrane protects bacteria from environmental 
stressors but also limits the ability of nutrients to enter the cell [1][2][3][4]. There are three 
ways to cross the outer membrane:  diffusion through non-specific protein porins, diffusion 
through stereospecific protein porins, and active transport with mediation from high-affinity 
outer membrane receptor proteins [2]. Molecules less than 600 Da, such as amino acids, sugars, 
and short peptides or oligosaccharides, can diffuse through porin channels [1][2]. Vitamin B12 
and iron-siderophore complexes are essential to bacteria but too large to pass through the 
porins. In order to uptake these valuable substances, specific high-affinity active transporters 
are needed. The TonB system transports energy from the cytoplasmic membrane (generated 
through an action potential) to the outer membrane [3]. This energy transduction is executed 
through an unknown mechanism. 
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The TonB energy transduction system allows transporters to deliver B12 and iron-
siderophore complexes into the periplasmic space. Additionally, the TonB system contributes to 
the pathogenesis by Gram-negative bacteria [3]. Ferric hydroxide complexes, the form that iron 
takes in the presence of oxygen, are insoluble. To reconcile this, E. coli secretes siderophores 
(Greek: “iron bearer”) that have an extremely high affinity for iron. TonB then allows the iron-
siderophore complexes to transverse the outer membrane. Iron is an important prosthetic 
group and cofactor for Gram-negative bacteria [4]. 
There are three components to antibiotic resistance in Gram-negative bacteria:  
degradation by bacteria-secreted enzymes, outer-membrane blockage, and a pump that 
removes the antibiotic as it enters—efflux. This paper focuses on efflux. It has been suggested 
that the TonB system drives efflux [5][6]. 
 
Materials and Methods:  
To study TonB, Gram-negative bacteria Escherichia coli were used. E. coli is the most 
commonly used bacteria in the laboratory setting. However, “the P. aeruginosa TonB gene 
complemented TonB mutations in both Escherichia coli and Pseudomonas putida WCS358, 
highlighting the interchangeability of action in different organisms” [5]. Since different Gram-
negative bacteria have similar TonB systems, this research has wider implications than solely 
the model organism E. coli. 
This research on antibiotic resistance was conducted over the past two years in Dr. Ray 
Larsen’s microbiology laboratory. Nine strains of Escherichia coli that have single stain deletions 
on a W3110 background were used:  W3110- wildtype, RA1079 (ΔfepA), RA1054 (ΔtolC), 
RA1055 (ΔacrA), RA1056 (ΔacrB), RA1038 (ΔtolA), KP1052 (Δfur⁻), KP1270 (ΔaroB⁻), KP1344 
(ΔTonB⁻)—the parenthetical information being the single-gene deletions. FepA, fur⁻, and TonB⁻ 
genes are needed for iron uptake; the tolA gene is needed for outer membrane integrity; the 
acrA, acrB, and tolC genes are needed for efflux; the aroB⁻ gene insertion brings too much iron 
into the cell. 
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 Basic laboratory procedures in bacteriology were used. The nine strains of Eshcherichia 
coli were cultured on agar plates under refrigeration. The wild type E. coli, W3110, was the 
control. 
A single bacterial colony of each strain was put in broth (five milliliters of lysogeny broth 
in separate large test tubes); these cultures were incubated with shaking overnight. The next 
day, one hundred microliters of each broth culture was pipetted into separate small test tubes. 
Three milliliters of hot T-top agar was pipetted into each small test tube (cells suspended in T-
top) and immediately poured onto T-top agar plates, one plate per strain. Three pre-prepared 
antibiotic discs (same antibiotic, i.e. in triplicate) were placed on each plate. Plates were put in 




Fig. 2. Example of zones of inhibition, measured in millimeters [7] 
 
This procedure was repeated for each of the following antibiotics:  rifampicin, 
vancomycin, erythromycin, and ceftazidime. Also, ten microliters of a 50:50 EDTA/SDS 
detergent mixture was tested against the strains in triplicate by pipetting 10μL onto blank discs. 




Fig. 3. Pour plates of the nine strains with four separate antibiotics in triplicate on discs 
 
Results: 
Results of Preliminary Studies-  This research builds on laboratory research previously 
conducted by Dr. Ray Larsen. 
TonB mutants were less susceptible (smaller kill zone) than efflux mutants to the 
antibiotic erythromycin. Also, TonB mutants were less susceptible than efflux mutants to 
deoxycholate. However, TonB mutants were more susceptible than efflux mutants to 
rifampicin. 
 
Fig. 4. TonB⁻ strains (yellow) do not correlate with the efflux strains (red) 
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 The integrity of the outer membrane in the TonB strains is intact based on the amount 
of outermembrane protein observed in TonB strains, which was a similar amount compared to 
the wildtype. 
 
Fig. 5. Immunoblotting of SDS-PAGE resolved samples; used to determine that TonB had not 
shed its outer membrane 
 
Results of this project- 
The aroB mutant, which cannot produce a siderphore and consequently has less iron 
uptake similar to the TonB mutant, had the same susceptability as the TonB mutant for 
erythromycin, rifampicin, and vancomycin and similar susceptability for ceftazidime and 
EDTA/SDS. 
The efflux mutants were more susceptable to erythromycin than the TonB mutant. All 
strains were fairly susceptable to rifampicin, with the mutants being slightly more so than the 
wildtype. The iron and the efflux strains were resistant to vancomycin, while the barrier mutant 
was susceptable. The efflux mutants were more susceptable to EDTA/SDS than the iron and 
barrier mutants and the wildtype. The barrier mutant and the mutant that takes in excess iron 
(fur⁻) were susceptable to ceftazidime; the other iron mutants and the wildtype were slightly 
more susceptable than the efflux mutants. 
 
Honors Project, Gombash 8 
 
 
Fig. 6. TonB⁻ strain (yellow) does not correlate with the efflux strains (red); rather, it is similar to 




      Zone of Inhibition (mm) 
Fig. 7. Complete set of tests on nine strains of Escherichia coli 
 























Fig. 8. Recorded triplicate values of kill zones (mm) for vancomycin and erythromycin 
 
Conclusion: 
Efflux mechanisms are important for erythromycin resistance. Efflux mechanism and 
barrier functions are both important for rifampicin resistance. Efflux is most likely not 
important for vancomycin resistance. 
Loss of the integrity of the outer membrane (barrier) is more important for the 
susceptability of E. coli to vancomycin. 
While it has been suggested that TonB drives efflux [5][6], research does not confirm 
this:  the TonB⁻ mutant was unrelated to the acrA, acrB, and tolC mutants (efflux mutants) for 
the tested antibiotics. For example:  with erythromycin, the TonB mutant strain was very 
resistant while each of the efflux mutants was not. 
It is already understood that TonB is important for iron transport. Iron is growth-
limiting, generally speaking, and important for bacterial virulence [8]. The results suggest that 
TonB mutants are more susceptible to certain antibiotics because they are iron limited, not 
because TonB plays a specific role in antibiotic efflux in E. coli. 
 
Discussion: 
Public Health & Antibiotic Resistance-  The majority of this research focused on microscopic 
mechanisms of antibiotic resistance. Understanding how microorganisms resist antibiotics is 
important to public health. The implications of understanding the TonB system may be far 
reaching. “When more is understood about the mechanism of TonB function, it may be possible 
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to design therapeutics that attack TonB directly” [4]. Knowing the specific role of TonB in E. coli 
and other gram-negative bacteria is vital. Gram-negative bacteria are especially threatening 
because they are becoming increasingly more resistant to common drugs, and there are not a 
lot of new drugs in production to treat these infections [9][10]. As microbiologists Ratledge and 
Dover assert:  “The only reason for studying a pathogen is to learn how to kill it” [11]. 
Bacteria are becoming increasingly resilient to previously effective treatments; this is 
termed antibiotic resistance (ABR). The CDC has set threat levels for bacteria [12]. Vancomycin-
resistant Staphylococcus aureus, erythromycin-resistant group A Streptococcus, and 
clindamycin-resistant group B Streptococcus are all considered “concerning threats,” meaning 
these bacteria should be monitored, but there may be other therapeutic options. Multidrug-
resistant Acinetobacter, drug resistant Campylobacter, extended spectrum Enterobacteriaceae 
(ESBL), vancomycin-resistant Enterococcus (VRE), multidrug-resistant Pseudomonas aeruginosa, 
drug-resistant non-typhoidal Salmonella, drug-resistant Salmonella serotype typhi, drug-
resistant Shigella, methicillin-resistant Staphylococcus aureus (MRSA), drug-resistant 
Streptococcus pneumoniae, and drug-resistant tuberculosis are all considered “serious 
threats.” Serious threats of ABR may have some therapeutic options but require monitoring and 
prevention. Most concerning are the “urgent threat” that require the public attention and 
limited transmission because of little or no other treatment options. One urgent threat is 
Clostridium difficile (CDIFF), which causes life-threatening diarrhea and is commonly a 
nosocomial infection. It causes 250,000 infection, 14,000 deaths, and over a billion dollars in 
medical care per year. Another urgent threat is carbapenem-resistant Enterobacteriaceae 
(CRE), which causes a bloodstream infection and is often a nosocomial infection. There are 
9,000 drug-resistant infections (7,900 Klebsiella spp.; 1,400 E. coli) and 600 deaths per year. The 
last urgent threat listed by the CDC is drug-resistant Neisseria gonorrhoeae, an STD. Of the 
820,000 gonococcal infections per year, 246,000 are drug-resistant infections (188,600 
tetracycline resistant, 11,480 less susceptible to cefixime, 3,280 less susceptible to ceftriaxone, 
and 2,400 less susceptible to azithromycin). 
 Bacteria are becoming more resistant to previously effective treatments for a number of 
reasons [12]. First and foremost, use of antibiotics, in general, promotes resistance of 
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antibiotics. In a bacterial infection of millions of bacteria, few may have evolved to resist the 
antibiotic; they survive the treatment, and proliferate. Furthermore, these bacteria may 
conjugate with other bacteria, transferring antibiotic resistance. Since ABR is a natural process 
of bacterial evolution, it can be slowed but not stopped. Misuse/overuse of antibiotics also 
promotes ABR. This includes use of antibiotics unnecessarily for viral infections. Additionally, 
stopping the use of a course of antibiotics when symptoms improve contributes to ABR; taking 
the full course of an antibiotic prescription to prevent reinfection by the “fittest” bacteria that 
survived. Also, antibiotics are routinely given to livestock for nontherapeutic use (up to 70% of 
all antibiotics sold in the U.S.); if these animals acquire ABR, improper handling or processing of 
food could spread the resistant bacteria to humans [13]. 
ABR poses a significant threat to public health. The CDC estimates that more than two 
million people in the United States are infected with bacteria resistant to antibiotics each year, 
directly resulting in the death of at least 23,000 people [12]. ABR poses a significant economic 
burden, as well. Direct healthcare costs of ABR is estimated at $20 billion and over $35 billion in 
lost wages, extended stays in hospitals, and premature deaths. 
Unfortunately, our economic model encourages misuse and overuse of antibiotics 
because drug sales are tied to reimbursement. Since 1987, no new antibiotic classes with novel 
mechanisms of action have been discovered [14]. Of the few antibiotics in the Research & 
Development (R&D) pipeline targeted at gram-negative bacteria, none have a novel mechanism 
of action [15]. 
 There are a number of things we can do to combat ABR. The CDC recommends four 
actions for this fight:  preventing infection (safe food handling, hand washing, immunizations, 
etc.) and the spread of resistance (using antibiotics only when needed and as directed), tracking 
(for further strategy development on prevention), improving prescribing/stewardship of 
antibiotics (stop inappropriate and unnecessary use), and developing new antibiotics and 
diagnostic testing (new drugs to replace the ones that have stopped working) [12]. One of the 
barriers to the R&D of new antibiotics is a lack of incentive for pharmaceutical companies. 
Currently, the R&D of antibiotics requires less clinical trial development time and carries 
additional five years of market exclusivity than other drugs [16]. However, antibiotics are 
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administered over a short span of time and do not carry the financial incentive of lifelong use as 
drugs that treat chronic conditions. 
Antibiotics are three times more likely to be withdrawn from the market than non-
antibiotics [16]. We do not just need new antibiotics; we need new, better antibiotics. 
 
Further Research- A follow up research question may be:  does varying the amount of iron in 
the medium change the susceptibility of E. coli to antibiotics? To test this, enriched medium 
(with additional iron) and minimal medium (with less or no iron) could be used. The aroB and 
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Fig. 9. Poster of findings 
Presentation of Research 
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Fig. 10. (above) flyer for Pittsburgh Bacterial Meeting 
Fig. 11. (below) Presenting research at the poster session at the Pittsburgh Bacterial Meeting 
 
Sources: 
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